Anlotinib Hydrochloride not checked
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
6 active
28 in total · 1 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.”In the company’s words, NCT05830500 on ClinicalTrials.gov
- Tested for
- Medullary Thyroid Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Advanced Hepatocellular Carcinoma (HCC), Endometrial Cancer, Pancreatic Neoplasms
- Main trialPhase 4
- “This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.”In the company’s words, NCT05830500 on ClinicalTrials.gov
- Other names
- Anlotinib
Other drugs for Medullary Thyroid Cancer
- SelpercatinibEli Lilly · Phase 3
- SNH-118110ScinnoHub Pharmaceutical Co., Ltd. · Phase 1
- 225Ac-ETN029Novartis · Phase 1
- CabozantinibExelixis · Marketed (Phase 4 trial)
Coming up4
- NovPhase 2 trial completes · ClinicalTrials.gov
- DecPhase 3 trial completes · ClinicalTrials.gov
- Jun 2027Phase 4 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials28
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Jun 2027 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | |
| Phase 3Recruiting | Aug 2024 | Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. | |
| Phase 3Active, not recruiting | 31 Dec 2024 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | |
| Phase 3Active, not recruiting | Dec 2026 | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | |
| Phase 3Not yet recruiting | Dec 2027 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | |
| Phase 2Recruiting | Nov 2026 | Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms | |
| Phase 3Unknown | 18 Mar 2022 | A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer | |
| Phase 3Unknown | Dec 2022 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) | |
| Phase 3Unknown | Dec 2022 | A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | |
| Phase 3Unknown | Jun 2024 | A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma | |
| Phase 3Unknown | Oct 2024 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | |
| Phase 3Unknown | Oct 2024 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | |
| Phase 3Unknown | Jun 2025 | A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer | |
| Phase 2Terminated | 27 Sep 2022 | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer | |
| Phase 2Unknown | 31 Dec 2022 | A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma | |
| Phase 2Unknown | May 2023 | A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma | |
| Phase 2Completed | 9 Nov 2023 | A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer | |
| Phase 2Unknown | Dec 2023 | A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | |
| Phase 2Terminated | 1 Feb 2024 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. | |
| Phase 1/2Unknown | 31 Dec 2021 | A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer | |
| Phase 1/2Unknown | Oct 2022 | To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer | |
| Phase 1/2Terminated | 25 Aug 2023 | A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | |
| Phase 1Unknown | Jun 2023 | Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients | |
| Phase 1Terminated | 27 Nov 2023 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | |
| Phase 1Unknown | Mar 2025 | A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. | |
| Phase 1Terminated | 4 Jun 2025 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). | |
| Phase 1Terminated | 18 Jun 2025 | TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors | |
| Phase 3Ended | not given | A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial,Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026